The Standards Alphabet Soup
Anyone who has worked in clinical data management is familiar with the alphabet soup of standards that governs clinical trials: CDISC, CDASH, SDTM, ADaM, SEND, USDM, HL7 FHIR, ICH M11, SNOMED, MedDRA, LOINC. Each standard exists for a reason. Each solves a specific problem in a specific context. And each, in isolation, is genuinely useful.
The problem is that these standards exist in silos. A protocol authored in Word has no formal relationship with the SDTM dataset that will eventually hold its study data. The eCRF built in the EDC system has no machine-readable connection to the eligibility criteria defined in the protocol. The regulatory submission package contains no structured reference to the endpoints that were originally defined during study design.
The result is massive manual translation work at every boundary in the clinical development lifecycle - with every translation introducing the risk of error, inconsistency, and delay.
"True interoperability is not about exporting data in a common format. It is about preserving the semantic meaning of data as it moves between systems."
What Each Standard Does
The Clinical Data Interchange Standards Consortium defines data standards for clinical trial data exchange. CDASH defines how data should be collected; SDTM defines how it should be submitted to regulators; ADaM defines how it should be structured for analysis. CDISC standards are effectively mandatory for regulatory submissions to the FDA, EMA, and PMDA.
The TransCelerate Unified Study Definitions Model defines a standardized, machine-readable representation of the clinical study protocol. It specifies the data entities and relationships that constitute a protocol - endpoints, eligibility criteria, arms, epochs, activities, and schedules - creating the foundation for true digital protocol data flow.
Fast Healthcare Interoperability Resources is the dominant standard for healthcare data exchange. Its growing adoption in clinical trials enables sponsors to connect study systems to healthcare data sources - electronic health records, real-world data repositories, patient registries - creating new possibilities for decentralized and data-rich study designs.
The International Council for Harmonisation's M11 guideline establishes a harmonized template and structured content standard for clinical study protocols. M11 aligns closely with USDM concepts, providing regulatory backing for the digital protocol approach and establishing a common framework that spans FDA, EMA, and PMDA requirements.
The Cost of Fragmentation
The cost of non-interoperability is staggering - and largely invisible because it has been treated as the normal cost of doing business. Manual re-entry of data between systems is the single largest source of protocol-related errors in clinical development. An eligibility criterion written in the protocol must be manually translated into the eCRF, the EDC system configuration, the site training materials, and the statistical analysis plan. Each translation is an opportunity for inconsistency.
Research suggests that protocol amendments - 40% of which are avoidable - often trace back to inconsistencies introduced during manual translation between systems and documents. These amendments cost the industry an estimated $500,000 per amendment on average, not counting the timeline delays and regulatory exposure they create.
- Manual re-entry of protocol data into EDC, IRT, and eCOA systems: estimated 4–8 weeks per study
- Inconsistencies between protocol and eCRF requiring amendment: industry average 2.3 amendments per study
- Manual document generation from protocol data: estimated 6–12 weeks per study for core document set
- Regulatory submission preparation time attributable to data format conversion: estimated 20–30% of total submission effort
What Interoperability Really Means
True interoperability does not mean that systems can export data in a common file format. It means that the semantic meaning of data is preserved as it moves between systems - that "primary endpoint" in the protocol data model means the same thing as "primary endpoint" in the EDC, the statistical analysis plan, and the regulatory submission package.
This semantic interoperability requires shared ontologies and standards-aligned data models. It requires technology vendors to build on common foundations rather than proprietary data structures. And it requires sponsors to demand standards alignment from their technology partners - asking not just "can your system export CDISC-compliant data?" but "is your data model natively aligned with USDM, and can it communicate directly with CDISC-aligned downstream systems without custom integration?"
Industry Momentum
The industry is moving - slowly but with increasing momentum. The FDA's acceptance of the ICH M11 guideline provides regulatory backing for structured protocol standards. TransCelerate's USDM initiative has attracted participation from the majority of top-20 global pharmaceutical companies. And a growing number of technology vendors - including Trials.ai - are building platforms that are natively aligned with these standards.
The tipping point will come when leading sponsors require USDM-native tools as a condition of their technology vendor relationships. When the standard is demanded by buyers, adoption by sellers follows quickly. Several large sponsors have already begun including USDM alignment in vendor RFP requirements - a signal that the tipping point is approaching.
Where We're Heading
The endpoint of this transition is a clinical development ecosystem where data flows from study concept to regulatory submission without manual transcription. Where a change to an eligibility criterion in the protocol automatically propagates to the EDC, the informed consent form, the site training materials, and the statistical analysis plan. Where every system in the ecosystem shares a common semantic understanding of what a clinical trial is.
This is not science fiction. The standards exist. The technology exists. What is required is the organizational commitment to build on these standards - from technology vendors, from sponsors, and from the regulatory bodies that set the rules of the road. The clinical trials of 2030 will look fundamentally different from those of today. The organizations building on standards-aligned infrastructure now will be positioned to benefit from that transformation.